Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION Labeling negotiator in a biologics company planning a biosimilar pathway has one working extract — 505(b)(2) literature-to-product bridge table — after a competitor label that just got a narrower indication. If 505(b)(2) literature-to-product bridge table cannot support to drop a secondary, the only defensible Pharma & Life Sciences output is hold.

DECISION Labeling negotiator in a biologics company planning a biosimilar pathway must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after a competitor label that just got a narrower indication.

HYPOTHESES TO TEST 1. Labeling negotiator can defend Proceed under protocol from 505(b)(2) literature-to-product bridge table after a competitor label that just got a narrower indication in a Pharma & Life Sciences challenge. 2. Labeling negotiator cannot defend Proceed under protocol from 505(b)(2) literature-to-product bridge table; Pause the pathway is what the extract actually supports after a competitor label that just got a narrower indication. 3. A competitor label that just got a narrower indication never reached the population in 505(b)(2) literature-to-product bridge table — reopen intake, do not close to drop a secondary. 4. Two facts in 505(b)(2) literature-to-product bridge table after a competitor label that just got a narrower indication conflict for labeling negotiator; hold this FDA Response and Labeling file.

ANALYSIS REQUIRED 1. Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim labeling negotiator would keep. 2. Map FDA-response timing and owner in a biologics company planning a biosimilar pathway. 3. Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a competitor label that just got a narrower indication. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read 505(b)(2) literature-to-product bridge table against a competitor label that just got a narrower indication and write the one fact that would move to drop a secondary for labeling negotiator.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (505(b)(2) literature-to-product bridge table after a competitor label that just got a narrower indication). Lead with the Pharma & Life Sciences option 505(b)(2) literature-to-product bridge table can support after a competitor label that just got a narrower indication, then the two facts that force it, then the Monday action for labeling negotiator in a biologics company planning a biosimilar pathway.